Pieris Historical Cash Flow
| PIRS Stock | USD 16.25 0.58 3.45% |
Analysis of Pieris Pharmaceuticals cash flow over time is an excellent tool to project Pieris Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change To Account Receivables of 5.6 M or Total Cash From Financing Activities of 22.4 M as it is a great indicator of Pieris Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Pieris Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pieris Pharmaceuticals is a good buy for the upcoming year.
Pieris |
About Pieris Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Pieris balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Pieris's non-liquid assets can be easily converted into cash.
Pieris Pharmaceuticals Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Pieris Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Pieris Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Most accounts from Pieris Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Change To Liabilities is comparatively stable compared to the past year. Investments is likely to gain to about 10.1 M in 2024, despite the fact that Free Cash Flow is likely to grow to (51.3 M).
| 2021 | 2023 | 2024 (projected) | Issuance Of Capital Stock | 57.1M | 19.7M | 22.9M | Change To Netincome | 5.2M | 6.0M | 4.0M |
Pieris Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Pieris Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pieris Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (12.6M) | 8.2M | 47.3M | (79.1M) | (21.2M) | (20.2M) | |
| Free Cash Flow | (54.9M) | (48.6M) | (8.6M) | (61.0M) | (54.0M) | (51.3M) | |
| Change In Working Capital | (32.1M) | (16.4M) | 30.5M | (33.4M) | (7.4M) | (7.0M) | |
| Begin Period Cash Flow | 74.9M | 62.3M | 70.4M | 117.8M | 38.6M | 46.0M | |
| Other Cashflows From Financing Activities | 1.2M | 491K | 2.0M | 292K | 19.8M | 20.8M | |
| Depreciation | 1.0M | 2.1M | 2.4M | 2.8M | 1.8M | 1.2M | |
| Other Non Cash Items | (69K) | 330K | (30K) | (467K) | (22.5M) | (21.4M) | |
| Capital Expenditures | 2.5M | 2.7M | 949K | 1.0M | 171K | 162.5K | |
| Total Cash From Operating Activities | (52.5M) | (45.9M) | (7.7M) | (59.9M) | (53.8M) | (51.1M) | |
| Change To Account Receivables | (4.1M) | 5.3M | (1.8M) | (2.6M) | 5.3M | 5.6M | |
| Net Income | (25.5M) | (37.2M) | (45.7M) | (33.3M) | (24.5M) | (25.8M) | |
| Total Cash From Financing Activities | 32.2M | 10.1M | 59.1M | 7.2M | 19.8M | 22.4M | |
| End Period Cash Flow | 62.3M | 70.4M | 117.8M | 38.6M | 17.4M | 16.5M | |
| Sale Purchase Of Stock | 48.5M | 32.2M | 10.1M | 59.1M | 68.0M | 71.4M | |
| Total Cashflows From Investing Activities | (8.9M) | 9.8M | 39.2M | (949K) | (1.1M) | (1.1M) | |
| Cash And Cash Equivalents Changes | 37.0M | (10.5M) | 3.4M | 50.5M | 58.1M | 61.0M | |
| Change To Liabilities | 13.3M | (28.2M) | (18.9M) | 36.5M | 42.0M | 44.0M | |
| Investments | 12.3M | 41.9M | (949K) | (21.2M) | 9.7M | 10.1M | |
| Change Receivables | 12.5M | (4.1M) | 5.3M | (1.8M) | (2.1M) | (2.0M) | |
| Stock Based Compensation | 5.4M | 5.1M | 5.2M | 4.4M | 3.3M | 3.9M | |
| Cash Flows Other Operating | (3.9M) | 523K | (1.4M) | (4.2M) | (3.8M) | (3.6M) | |
| Change To Operating Activities | (690K) | (799K) | (2.9M) | 5.7M | 6.6M | 6.9M | |
| Change To Netincome | 3.2M | 4.1M | 5.4M | 5.2M | 6.0M | 4.0M | |
| Issuance Of Capital Stock | 31.0M | 9.6M | 57.1M | 6.9M | 19.7M | 22.9M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.